{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:43:14Z","timestamp":1790739794315,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.neuropharm.2015.01.012","type":"journal-article","created":{"date-parts":[[2015,1,31]],"date-time":"2015-01-31T05:27:50Z","timestamp":1422682070000},"page":"52-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"C","title":["Activity of serotonin 5-HT1A receptor \u2018biased agonists\u2019 in rat models of Parkinson's disease and l-DOPA-induced dyskinesia"],"prefix":"10.1016","volume":"93","author":[{"given":"H.","family":"Iderberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Varney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Cenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Newman-Tancredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2015.01.012_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/syn.20195","article-title":"Effects of sarizotan on the corticostriatal glutamate pathways","volume":"58","author":"Antonelli","year":"2005","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib2","series-title":"Statistical Methods in Medical Research","author":"Armitage","year":"2001"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.bjp.0706859","article-title":"Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat","volume":"149","author":"Assie","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib4","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.25366","article-title":"Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nbd.2012.10.013","article-title":"Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat","volume":"50","author":"Breger","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2006.01.027","article-title":"Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase","volume":"534","author":"Bruins Slot","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib8","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1523\/JNEUROSCI.2079-07.2007","article-title":"Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease","volume":"27","author":"Carlsson","year":"2007","journal-title":"J.\u00a0Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib9","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain J. Neurol."},{"issue":"Suppl.\u00a02","key":"10.1016\/j.neuropharm.2015.01.012_bib10","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.parkreldis.2008.04.021","article-title":"Involvement of the serotonin system in L-dopa-induced dyskinesias","volume":"14","author":"Carta","year":"2008","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib11","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib12","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2174\/187152711797247885","article-title":"Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease","volume":"10","author":"Cenci","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1749-6632.1998.tb10229.x","article-title":"Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex","volume":"861","author":"Chen","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib14","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0306-4522(93)90240-G","article-title":"Serotoninergic terminal transporters are differentially affected in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram","volume":"54","author":"Chinaglia","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.expneurol.2011.02.012","article-title":"Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats","volume":"229","author":"Dupre","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","article-title":"The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy","volume":"87","author":"Eskow","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/syn.20630","article-title":"The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats","volume":"63","author":"Eskow","year":"2009","journal-title":"Synapse"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.neuropharm.2015.01.012_bib19","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.1002\/mds.22028","article-title":"The history of dopamine and levodopa in the treatment of Parkinson's disease","volume":"23","author":"Fahn","year":"2008","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib73","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0166-4328(96)00118-0","article-title":"Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist","volume":"73","author":"Fletcher","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.nbd.2011.05.004","article-title":"Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia","volume":"43","author":"Garcia","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s10571-010-9509-9","article-title":"The roles of striatal serotonin and L -amino-acid decarboxylase on L-DOPA-induced dyskinesia in a hemiparkinsonian rat model","volume":"30","author":"Gil","year":"2010","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib23","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/BF00174065","article-title":"Lithium decreases 5-HT1A and 5-HT2 receptor and alpha 2-adrenoceptor mediated function in mice","volume":"90","author":"Goodwin","year":"1986","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys","volume":"15","author":"Gregoire","year":"2009","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","article-title":"Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease","volume":"510","author":"Halliday","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ana.410270405","article-title":"Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease","volume":"27","author":"Halliday","year":"1990","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-3223(90)90627-E","article-title":"Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites","volume":"28","author":"Hamik","year":"1990","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pneurobio.2011.08.004","article-title":"The serotonergic system in Parkinson's disease","volume":"95","author":"Huot","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.111.184093","article-title":"Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?","volume":"339","author":"Huot","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib31","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\u2216 increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib32","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.euroneuro.2010.03.001","article-title":"An in\u00a0vivo pharmacological evaluation of pardoprunox (SLV308)\u2013a novel combined dopamine D(2)\/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease","volume":"20","author":"Jones","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib33","first-page":"133","article-title":"Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease","volume":"54","author":"Kannari","year":"2002","journal-title":"No To Shinkei"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1124\/jpet.110.173948","article-title":"Functional selectivity and biased receptor signaling","volume":"336","author":"Kenakin","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0014-2999(01)01011-1","article-title":"5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential","volume":"420","author":"Koek","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib36","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/j.1471-4159.2009.06556.x","article-title":"L-DOPA-induced dopamine efflux in the striatum and the substantia Nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia","volume":"112","author":"Lindgren","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib37","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1476-5381.2010.00738.x","article-title":"Preferential in\u00a0vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors","volume":"160","author":"Llado-Pelfort","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib38","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/cercor\/bhr220","article-title":"5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons","volume":"22","author":"Llado-Pelfort","year":"2012","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib40","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1046\/j.1471-4159.2003.01632.x","article-title":"Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia","volume":"84","author":"Lundblad","year":"2003","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib41","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.brainres.2006.07.003","article-title":"Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions","volume":"1112","author":"Matsubara","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00213-006-0680-0","article-title":"Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease","volume":"192","author":"Mignon","year":"2007","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib43","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00001756-200505120-00009","article-title":"8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease","volume":"16","author":"Mignon","year":"2005","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fncir.2014.00021","article-title":"Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease","volume":"8","author":"Miguelez","year":"2014","journal-title":"Front. Neural Circuits"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10799899209074797","article-title":"Brainstem 5-hydroxytrytamine1A binding sites are not down-regulated by agonists which induce tolerance in the rat: myoclonus and other serotonergic behaviors","volume":"12","author":"Murthy","year":"1992","journal-title":"J.\u00a0Recept. Res."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib46","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1471-4159.2011.07598.x","article-title":"Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning","volume":"120","author":"Nahimi","year":"2012","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib47","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00210-003-0788-2","article-title":"Comparison of hippocampal G protein activation by 5-HT1A receptor agonists and the atypical antipsychotics clozapine and S16924","volume":"368","author":"Newman-Tancredi","year":"2003","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib48","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1017\/S1461145704005000","article-title":"Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia","volume":"8","author":"Newman-Tancredi","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib49","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1476-5381.2008.00001.x","article-title":"Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist","volume":"156","author":"Newman-Tancredi","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/npy.11.12","article-title":"Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders","volume":"1","author":"Newman-Tancredi","year":"2011","journal-title":"Neuropsychiatry"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib51","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1254\/jphs.08313FP","article-title":"Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice","volume":"109","author":"Ohno","year":"2009","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib52","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","article-title":"Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)","volume":"27","author":"Olanow","year":"2004","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib53","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mds.25364","article-title":"Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease","volume":"28","author":"Olanow","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib54","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.neuropharm.2011.05.021","article-title":"Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation","volume":"61","author":"Ostock","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib55","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0006-2952(01)00575-5","article-title":"Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins","volume":"61","author":"Pauwels","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib56","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib57","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0006-3223(85)90194-5","article-title":"Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors","volume":"20","author":"Peroutka","year":"1985","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib58","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib59","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00008877-200006000-00013","article-title":"Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy","volume":"11","author":"Prinssen","year":"2000","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib61","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A\u00a0mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib62","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib63","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/cercor\/bhh070","article-title":"Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex","volume":"14","author":"Santana","year":"2004","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib64","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0006-8993(83)90993-9","article-title":"Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease","volume":"275","author":"Scatton","year":"1983","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib65","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.nbd.2012.03.038","article-title":"Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease","volume":"47","author":"Shin","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib66","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.nbd.2013.09.021","article-title":"The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation","volume":"62","author":"Shin","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib67","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","article-title":"Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats","volume":"10","author":"Tanaka","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2015.01.012_bib68","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejphar.2010.09.013","article-title":"Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats","volume":"649","author":"Tani","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib69","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1523\/JNEUROSCI.0944-06.2006","article-title":"Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia","volume":"26","author":"Westin","year":"2006","journal-title":"J.\u00a0Neurosci. Off. J. Soc. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib70","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib71","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.nbd.2010.08.004","article-title":"Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia","volume":"40","author":"Zeng","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2015.01.012_bib72","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0024-3205(00)00729-3","article-title":"Modulation of medical prefrontal cortical D1 receptors on the excitatory firing activity of nucleus accumbens neurons elicited by (-)-Stepholidine","volume":"67","author":"Zhu","year":"2000","journal-title":"Life Sci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815000283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815000283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T22:25:09Z","timestamp":1537914309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390815000283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":73,"alternative-id":["S0028390815000283"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.01.012","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of serotonin 5-HT1A receptor \u2018biased agonists\u2019 in rat models of Parkinson's disease and l-DOPA-induced dyskinesia","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}